Related Experiment Videos
Induction of glutathione content in murine melanocytes after transformation with c-H-ras oncogene
1Pharmacology/Toxicology Program, Washington State University, Pullman 99164-6510.
Abstract:
Malignant melanoma tumors are inherently resistant to anticancer drugs, yet the mechanism of this resistance is not understood. B16 melanoma, a spontaneous tumor which arose in the C57BL/6 mouse; BL6 melanoma, a highly invasive variant; and Mel-ab melanocytes, isolated from C57BL/6 mouse skin, were examined for intracellular glutathione (GSH) content. GSH was higher in BL6 and B16 cells than in Mel-ab cells, with the highest concentration in BL6 cells. Since GSH is thought to be involved in the resistance of many cells, including melanoma, to cytotoxic drugs, we determined whether intracellular GSH content was altered during transformation of Mel-ab cells. After transfection with pHO6T1 plasmid DNA, containing an activated c-H-ras oncogene flanked by transcriptional enhancers, 1.3% of successfully transfected Mel-ab melanocytes formed distinct colonies in soft agar, compared to 0.2% of cells transfected with control pHO6 plasmid without H-ras. Approximately 53% of the pHO6T1-transfected colonies isolated from soft agar grew in 5% CO2 in the absence of phorbol-12-myristate-13-acetate, a requirement for the extended growth of Mel-ab cells. Cells transfected with control pHO6 plasmid and non-transfected Mel-ab cells did not survive under these conditions. All of the isolated pHO6T1 transfected cells formed tumors when inoculated into C57BL/6 mice. Transformed cells had higher GSH content than non-transfected Mel-ab cells, whether expressed on a cellular or cell volume basis. Although the amount of oxidized glutathione was greater in the tumorigenic cells, this could not account for the overall increase in GSH. Neither glutathione S-transferase nor gamma-glutamyl transpeptidase activities were increased in the H-ras-transfected cells. Northern blot analysis confirmed H-ras-specific RNA in pHO6T1-transformed cells.
Insights
Malignant melanoma cells exhibit drug resistance, linked to increased intracellular glutathione (GSH). Oncogene activation via H-ras in melanocytes significantly elevated GSH levels, contributing to tumor formation and drug resistance.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Malignant melanoma tumors display inherent resistance to anticancer drugs.
- The underlying mechanisms of this drug resistance remain poorly understood.
- Intracellular glutathione (GSH) is implicated in cellular resistance to cytotoxic agents.
Purpose of the Study:
- To investigate the role of intracellular glutathione (GSH) content in melanoma drug resistance.
- To determine if oncogene activation alters GSH levels during melanoma cell transformation.
- To explore the relationship between H-ras oncogene expression and tumor development.
Main Methods:
- Quantification of intracellular glutathione (GSH) in B16 melanoma, BL6 melanoma, and Mel-ab melanocytes.
- Transfection of Mel-ab melanocytes with a c-H-ras oncogene plasmid (pHO6T1).
- Assessment of cell transformation, growth characteristics, tumor formation in mice, and enzyme activities (glutathione S-transferase, gamma-glutamyl transpeptidase).
Main Results:
- BL6 and B16 melanoma cells exhibited higher GSH content than Mel-ab melanocytes.
- Mel-ab melanocytes transfected with the H-ras oncogene (pHO6T1) showed increased GSH levels compared to control cells.
- Transformed cells demonstrated enhanced growth, tumor formation in vivo, and elevated GSH content on both cellular and cell volume bases.
- Increased oxidized glutathione and H-ras-specific RNA were observed in transformed cells, but glutathione S-transferase and gamma-glutamyl transpeptidase activities were not elevated.
Conclusions:
- Activation of the c-H-ras oncogene in melanocytes leads to increased intracellular GSH.
- Elevated GSH levels in H-ras-transformed cells correlate with enhanced tumorigenicity and potential drug resistance.
- This study provides insights into the molecular mechanisms underlying melanoma drug resistance and oncogene-induced transformation.